The global MRI-Compatible IV Infusion Pump Systems Market is estimated to be valued at USD 322.5 million in 2025 and is projected to reach USD 742.9 million by 2035, registering a compound annual ...
North America is projected to remain dominant in the global MRI-compatible IV infusion pump system market, according to a report by Future Market Insights (FMI). In North America, there is a surge in ...
New York, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global MRI Compatible IV Infusion Pumps Market 2022-2026" - https ...
Pending FDA approval, the upgraded Prometra Implantable Pump System for the targeted delivery of pain medication will feature MRI compatibility, Flowonix CEO Steve Adler told FierceDrugDelivery in an ...
Iradimed picked up an FDA nod for its MRI-compatible intravenous infusion pump system, which enables patients who can’t be disconnected from IV medication to undergo MRI scanning. The company will now ...
Iradimed Corporation announced that it has received FDA 510(k) clearance for its next-generation MRidium® 3870 IV Infusion Pump System, making it the only supplier of non-magnetic MRI-compatible ...
Roth MKM has resumed coverage of iRadimed (NASDAQ:IRMD) with a buy rating citing the company's position as the sole provider of MRI-compatible IV pumps. The firm has a $65 price target (~59% upside ...
Flowonix, maker of the implantable Prometra infusion pump for chronic pain patients, announced that it has raised $40 million in debt and equity financing, led by private equity fund Élevage Capital ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback